Overview
- Wang, H.S. et al. (2000) Mol. Pharmacol. 57, 1218.
Alomone Labs XE991 blocks KCNQ2/KCNQ3 channels heterologously expressed in Xenopus oocytes.A. Time course of KCNQ2/KCNQ3 maximal current amplitude, elicited by 700 ms voltage step from holding potential of -100 mV to -30 mV, delivered every 10 seconds. Application of 100 µM XE991 (#X-100) inhibits the KCNQ2/KCNQ3 current in a reversible manner (indicated by the horizontal bar). B. Representative current traces before and during application of 100 µM XE991 as indicated.
- Yeung, S.Y. and Greenwood, I.A. (2005) Br J Pharmacol. 146, 585.
- Zaczek, R. et al. (1998) Pharmacol. Exp. Ther. 285, 724.
- Fontán-Lozano, A. et al. (2009) Hippocampus 21, 22.
Voltage-gated K+ channels of the KCNQ family (KV7) are widely expressed in nerves and smooth muscles where their general role is to hyperpolarise the cell membrane and thereby dampen excitability1.
XE991 is a potent and selective blocker of KCNQ voltage-gated K+ channels. It blocks KV7.2 + KV7.3 (KCNQ2 + KCNQ3)/M-currents (IC50 = 0.6 μM) and KV7.1 (KCNQ1) homomeric channels (IC50 = 0.75 μM) but is less potent against KV7.1/minK channels (IC50 = 11.1 μM)1. Suppression of the M-current causes an increase in intrinsic excitability2. XE991 enhances acetylcholine release from rat brain slices (EC50 = 490 nM) and shows good in vivo potency and duration of action, suggesting utility in Alzheimer’s disease therapeutics2. It was demonstrated that XE991 enhances learning and memory in healthy mice3.
XE991 (#X-100) is a highly pure, synthetic, and biologically active compound.
Applications
Citations
Powered by Bioz- Muqeem, T. et al. (2018) J. Neurosci. 38, 3729.
- Nassoiy, S.P. et al. (2017) J. Biomed. Sci. 24, 8.
